Table of Contents

• Trial overview
• Who is being studied
• What the trial measures
• Trial design and phase
• Key patient terms

Trial overview

This clinical trial is studying Vortioxetine Hydrobromide in people with a recent diagnosis of schizophrenia.^[1] The study is described as an interventional trial, which means researchers give a study treatment and then measure the results.^[1]

The trial title says it is looking at an already authorized drug for other conditions in people with schizophrenia.^[1] The study is authorised and has 37 planned participants.^[1]

Who is being studied

The trial focuses on people with schizophrenia and schizophrenia spectrum disorders.^[1] The brief summary also says the study is for people with early psychosis, which means the early stage of a psychotic illness.^[1]

Psychosis is a mental state where a person may have trouble telling what is real.^[1] In this study, the main concern is not only the illness itself, but also cognitive problems linked with early psychosis.^[1]

What the trial measures

The main outcome is cognitive functioning improvement, measured by the change in BACS App scores.^[1] Cognitive functioning means thinking skills such as memory, attention, and planning.^[1]

BACS stands for Brief Assessment of Cognition in Schizophrenia, a test used to check thinking skills in people with schizophrenia.^[1] The summary says the score is tracked from baseline to Week 24, with additional time points at Week 26 and Week 50.^[1]

The study uses a Composite Z-score, which means several test results are combined into one overall score.^[1] This helps researchers see whether thinking skills improve over time.^[1]

Trial design and phase

This is a Phase 4 trial.^[1] Phase 4 studies usually look at an already authorized treatment in a real-world setting or for another use.^[1]

The intervention list includes several antipsychotic drugs, along with Vortioxetine Hydrobromide.^[1] The listed medicines are quetiapine, pimozide, chlorpromazine, risperidone, olanzapine, ziprasidone, aripiprazole, thioridazine, and haloperidol.^[1]

The study objective is to compare Vortioxetine with treatment as usual in early psychosis, with the main focus on cognition.^[1]

Key patient terms

Treatment as usual means the standard care a patient would normally receive outside the study.^[1] This gives researchers a way to compare the study treatment with regular care.^[1]

Baseline is the first measurement before treatment starts, and Week 24 is the main time point used to check change after treatment.^[1] The study also checks later time points at Week 26 and Week 50.^[1]

Interventional study means the research team gives a treatment rather than only observing people.^[1] In this trial, the goal is to see whether Vortioxetine Hydrobromide can help with cognitive problems in early psychosis.^[1]